All In Biotech

Drug Trial Radar · NCT07768189

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator's Choice of Capecitabine, Cetuximab, or Docetaxel in Participants With Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated With Platinum-based Chemotherapy and a PD-(L)1 Inhibitor

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Sep 29, 2026

Primary completion

Dec 2027

Study completion Mar 2029

Sponsor

Lead sponsor
Corbus Pharmaceuticals Inc.Industry
Sponsor type
Industry
Collaborators
CSPC Megalith Biopharmaceutical Co.,Ltd.
First posted
Aug 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum based chemotherapy or immunotherapy (using a check-point inhibitor) It will also learn about the safety of the drug and measure quality of life. The main questions it asks are: * What proportion of participants respond to CRB-701 measured using scans (CT or MRI) * What medical problems do participants experience when taking CRB-701. Researchers will compare CRB-701 with standard of care medicines (drugs that are normally used this disease). Participants will: * Attend clinic every three weeks to receive infusions of CRB-701 or standard of care medicines until the cancer cannot be measured or is not controlled by the treatment they are receiving. * Have a CT or MRI every 6 weeks to measure the effect on their cancer * Complete questionnaires to assess their health status.

Conditions

  • Oropharyngeal Carcinoma (OPC)

Interventions

  • CRB-701Drug

    CRB-701 3.6mg/Kg administered intravenously every 21 days (Q3W)

  • capcitabineDrug

    1250 mg/m2 twice daily on days 1-14 of each 21-day cycle

  • Cetuximab (EGFR inhibitor)Drug

    400mg/m2 loading dose followed by 250mg/m2 weekly as an IV infusion or 500mg/m2 every 2 weeks.

  • DocetaxelDrug

    75 mg/m2 as an IV infusion on day 1 of each 21-day cycle or 30 mg/m2 weekly to escalate to 40 mg/m2, if tolerated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (%)Time frame: Up to 24 months
  2. Overall Survival (months)Time frame: Approximately 3 years from randomization

Locations

111 sites in 14 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama · Not yet recruiting

  • The University of Arizona Cancer Center

    Tucson, Arizona · Not yet recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Not yet recruiting

  • University of California Los Angeles Westwood Cancer Center

    Los Angeles, California · Not yet recruiting

  • Stanford Medicine - Cancer Center

    Palo Alto, California · Not yet recruiting

  • Moores Cancer Center

    San Diego, California · Not yet recruiting

  • UCSF Head and Neck Surgery Cancer Program

    San Francisco, California · Not yet recruiting

  • UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado

    Colorado Springs, Colorado · Not yet recruiting

  • Yale School of Medicine

    Newhaven, Connecticut · Not yet recruiting

  • Medical Oncology Hematology Consultants

    Newark, Delaware · Not yet recruiting

  • Florida Cancer Specialists and Research Institute

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center Magnolia Campus

    Tampa, Florida · Not yet recruiting

  • University of Chicago

    Chicago, Illinois · Not yet recruiting

  • Iowa Health Care Holden Comprehensive Cancer Center

    Iowa City, Iowa · Not yet recruiting

  • University of Louisville Health

    Louisville, Kentucky · Not yet recruiting

  • University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland · Not yet recruiting

  • Greater Baltimore Medical Center

    Baltimore, Maryland · Not yet recruiting

  • Dana Faber Cancer Institute

    Boston, Massachusetts · Not yet recruiting

  • Barbara Ann Karmanos Cancer Institute - Wayne State University

    Detroit, Michigan · Not yet recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Not yet recruiting

  • Washington University in St. Louis

    St Louis, Missouri · Not yet recruiting

  • Nebraska Cancer Specialists - Methodist Estabrook Cancer Center

    Omaha, Nebraska · Recruiting

  • NYU Langone Health Perlmutter Cancer Center

    New York, New York · Not yet recruiting

  • Memorial Sloan Kettering

    New York, New York · Not yet recruiting

  • Gabrail Cancer Center and Research Center

    Canton, Ohio · Recruiting

  • Cleveland Clinic Main Campus

    Cleveland, Ohio · Not yet recruiting

  • The Ohio State University Comprehensive Cancer Center The Arthur G.James

    Columbus, Ohio · Not yet recruiting

  • Penn-Medicine - Abramson Cancer Center University of Pennsylvania

    Philadelphia, Pennsylvania · Not yet recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Not yet recruiting

  • MUSC Hollings Cancer Center

    Charleston, South Carolina · Not yet recruiting

  • Prisma Health Cancer Institute Multidisciplinary Center

    Greenville, South Carolina · Not yet recruiting

  • Tennessee Cancer Specialists

    Knoxville, Tennessee · Not yet recruiting

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee · Not yet recruiting

  • Texas Oncology

    Austin, Texas · Not yet recruiting

  • Texas Oncology

    Dallas, Texas · Not yet recruiting

  • UVA Health - Emily Couric Clinical Cancer Center

    Charlottesville, Virginia · Not yet recruiting

  • Fred Hutchinson Cancer Center Clinical - Seattle Cancer Care Alliance

    Seattle, Washington · Not yet recruiting

  • Northwest Cancer Center

    Vancouver, Washington · Not yet recruiting

  • Ordensklinikum Linz Barmherzige Schwestern

    Linz, Austria · Not yet recruiting

  • University Hospital Vienna

    Vienna, Austria · Not yet recruiting

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.